Denali Capital Acquisition Corp

Denali Capital Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 5, 2022 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex's discretion, into the Company's Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $119,772.04 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company , will go public via a merger with special purpose acquisition company Denali Capital Acquisition Corp in a $2.5 billion deal, the companies said on Tuesday.

Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal

NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the “Articles”) to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine times by an additional one month each time (the “Extension”).

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

Scilex Holding Co

Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company SCLX, and Denali Capital Acquisition Corp. DECA, a special purpose acquisition company, signed a letter of intent for a proposed business combination.

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company Denali Capital Acquisition Corp in a pre-transaction equity deal valued at up to $2 billion.

Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands corporation and special purpose acquisition company (Nasdaq: DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”).  The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.

Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination

Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination

NEW YORK , Dec. 29, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (Nasdaq: DECA) (the "Company") announced today that its previously announced extraordinary general meeting (the "Shareholder Meeting") originally scheduled for Thursday, January 4, 2024, at 9:00 AM, Eastern Time, is being postponed to Tuesday, January 9, 2024, at 9:00 AM, Eastern Time (the "Postponement"). There is no change to the physical location, the record date, the purpose or any of the proposals to be acted upon at the Shareholder Meeting.

Denali Capital Acquisition Corp. Announces Postponement of Extraordinary General Meeting From Thursday, January 4, 2024 to Tuesday, January 9, 2024

NEW YORK , July 13, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that an aggregate of $825,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its initial business combination by an additional three months, from the current deadline of July 11, 2023 to October 11, 2023. This is the second of the two three-month extensions permitted under the Company's governing documents.

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete an Initial Business Combination

NEW YORK , July 7, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that it intends to deposit into the Company's trust account an aggregate of $825,000 in order to further extend the period of time the Company has to consummate its initial business combination by an additional three months, from the current deadline of July 11, 2023 to October 11, 2023 (the "Extension"). In connection with the Extension, the Company expects to deposit the additional funds into the trust account on or before the current deadline of July 11, 2023.

Denali Capital Acquisition Corp. Announces Intention to Extend Deadline to Complete an Initial Business Combination

News for Denali Capital Acquisition Corp Stock (DECA)